The New Reality of Peptide Analysis
By James Strachan
June 1, 2026
Kelly Broster of Thermo Fisher Scientific explains why GLP-1 peptides are exposing the limits of traditional analytical workflows
12 min read
False
Advertisement
Technology & Manufacturing
Roving Reporter Asks: Where Is Real Progress Being Made in Manufacturing and Supply Chain?
May 28, 2026
IBTV speaks with industry leaders at Advanced Therapies London 2026 to explore how automation, AI, closed systems, and smarter supply chain models are helping advanced therapies move toward scalable delivery
Cell Therapy Manufacturing: A Medicine Maker’s “Dream”
May 25, 2026
Why CTMC CEO Jason Bock relishes the challenge of solving cell therapy’s most complex manufacturing and delivery problems
13 min read
Analytical Champions: Tao Chen
May 22, 2026
A new series championing analytical scientists in pharma begins with Genentech’s rising star
7 min read
Three Trends Shaping Multi-omics Sample Preparation
By Malin Karlsson
May 19, 2026
Maximizing insight from limited samples, aligning data across molecular layers, and building consistency from the first step
3 min read
Breaking the “Black Box” in Bioprocessing
May 14, 2026
Why understanding titer analytics is key to faster, more reliable biologics and gene therapy development
9 min read
Industrializing Organoids to Bridge the Predictability Gap
By Priya Baraniak
May 11, 2026
As regulators move away from animal testing, scalable organoid platforms and standardized iPSC inputs could help close the gap between preclinical models and human biology
4 min read
Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?
May 6, 2026
IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to explore advances in scaling cell and gene therapies
Trends and Challenges in Nitrosamine Testing: Part Five – Pharma’s Future
May 1, 2026
Our gurus return to discuss future directions for nitrosamine analysis and regulation within the pharmaceutical industry
3 min read
Manufacturing Viral Vectors for the Next Phase of CGT
April 30, 2026
As the sector matures, scalable vector production and robust analytical control are becoming essential to clinical and commercial success
7 min read
